Hepatitis C Treatments.

anti-HCV antiviral/COVID-19 treatment	Remdesivir	Lopinavir/Ritonavir	Hydroxychloroquine
Sofosbuvir 400 mg + Velpatasvir 100 mg	Weak interaction risk	Weak interaction risk	Weak interaction risk
Sofosbuvir 400 mg + Velpatasvir 100 mg + Voxilaprevir 100 mg	Weak interaction risk	Increase concentrations of Voxilaprevir - Association not recommended	Low to moderate interaction risk – Cardiac ECG monitoring and therapeutic drug monitoring of hydroxychloroquine concentrations
Glecaprevir 100 mg + Pibrentasvir 40 mg	Weak interaction risk	Increase concentrations of Glecaprevir and Pibrentasvir - Association not recommended	Moderate interaction risk – Cardiac ECG monitoring and therapeutic drug monitoring of hydroxychloroquine concentrations